It is very uncertain whether the intervention changes cefazolin versus cefazolin and gentamycin (median sternotomy) (very low certainty).
The intervention may leads to lower co‐amoxiclav or cefotaxime versus placebo (percutaneous endoscopic… (low certainty).
It is very uncertain whether the intervention changes daptomycin and cefazolin versus cefazolin (vascular surgery) (very low certainty).
It is very uncertain whether the intervention changes daptomycin versus vancomycin or semisynthetic penicillin (very low certainty).
It is very uncertain whether the intervention changes ertapenem versus piperacillin/tazobactam (very low certainty).
It is very uncertain whether the intervention changes moxifloxacin versus piperacillin/tazobactam followed by… (very low certainty).
Summary of findings: quinolone prophylaxis probably leads to higher all cause‐mortality compared with TMP‐SMZ prophylaxis (moderate certainty).
Summary of findings: quinolone prophylaxis probably leads to lower febrile patients and episodes compared with TMP‐SMZ prophylaxis (moderate certainty).
Summary of findings: quinolone prophylaxis probably leads to lower bacteraemia compared with TMP‐SMZ prophylaxis (moderate certainty).
It is very uncertain whether the intervention changes re‐infection (very low certainty).
It is very uncertain whether 10‐day trimethoprim changes persistent bacteriuria compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
It is very uncertain whether 10‐day trimethoprim changes persistent symptoms compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
It is very uncertain whether 10‐day trimethoprim changes recurrence compared with 10‐day trimethoprim+sulfamethoxazole (very low certainty).
It is very uncertain whether 10‐day cefadroxil changes persistent bacteriuria compared with 10‐day ampicillin (very low certainty).
It is very uncertain whether 10‐day cefadroxil changes persistent symptoms compared with 10‐day ampicillin (very low certainty).
It is very uncertain whether single‐dose fosfomycin changes persistent bacteriuria compared with single‐dose netilmicin (very low certainty).
It is very uncertain whether single‐dose fosfomycin changes recurrence compared with single‐dose netilmicin (very low certainty).
It is very uncertain whether the intervention changes persistent bacteriuria (very low certainty).
It is very uncertain whether the intervention changes recurrence (very low certainty).
Doxycycline+Rifampicin probably leads to higher total treatment failure compared with doxycycline+Streptomycin (moderate certainty).